Alunbrig 90 mg (Brigatinib TABLET) 90 MG

ALUNBRIG 90 MG tablets contain brigatinib, a medication used to treat certain types of cancer. This oral medication is manufactured by Takeda Canada Inc. and is available in 7, 28, or 30 tablet packs.

Strength

90 MG

Pack Size

7/28/30

Manufacturer / TM Owner

TAKEDA CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ALUNBRIG 90 MG is primarily used in the treatment of non-small cell lung cancer (NSCLC). This medication targets specific genetic mutations to help manage cancer growth. Patients often wonder, 'What is brigatinib used for?' and the answer lies in its role as a targeted therapy for advanced NSCLC.

Side Effects

Common effects of ALUNBRIG 90 MG may include nausea, fatigue, and cough. Some users also report diarrhea and increased appetite. These effects can vary widely among individuals, and it's important to consult a healthcare provider for personalized advice.

Precautions & Warnings

ALUNBRIG 90 MG should be handled with care, stored at room temperature, and kept out of reach of children. Patients should follow their healthcare provider's instructions regarding administration and monitor for any adverse reactions. Always inform your healthcare provider about any pre-existing conditions before starting this medication.

Avoid Interactions

ALUNBRIG 90 MG may interact with certain medications, including strong CYP3A inducers and inhibitors. It's important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol consumption should also be discussed with a healthcare provider.

Frequently Asked Questions

ALUNBRIG 90 MG is used to treat non-small cell lung cancer (NSCLC) with specific genetic mutations.

ALUNBRIG 90 MG is taken orally, typically once daily, as prescribed by a healthcare provider.

Common side effects may include nausea, fatigue, cough, diarrhea, and increased appetite.

ALUNBRIG 90 MG may interact with certain medications, so it's important to consult a healthcare provider before combining it with other drugs.

Long-term use of ALUNBRIG 90 MG should be monitored by a healthcare provider to ensure safety and effectiveness.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.